Cellectar Biosciences Inc. (NASDAQ:CLRB) has a beta of 1.63. The stock’s Relative Strength Index (RSI) is 70.67, with weekly volatility at 6.86% and ATR at 0.11. The CLRB stock’s 52-week price range has touched low of $1.01 and a $2.98 high. Its shares traded higher over the last trading session, gaining 8.98% on 06/03/21. The shares fell to a low of $1.63 before closing at $1.82. Intraday shares traded counted 0.93 million, which was -27.82% lower than its 30-day average trading volume of 729.46K. CLRB’s previous close was $1.67 while the outstanding shares total 48.14M.
Investors have identified the Biotechnology company Cellectar Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $93.00 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Cellectar Biosciences Inc. (CLRB) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 54.4 million total, with 5.02 million as their total liabilities.
CLRB were able to record -4.75 million as free cash flow during the 08/16/2021 quarter of the year, this saw their quarterly net cash flow reduce by -3.54 million. In cash movements, the company had a total of -4.75 million as operating cash flow.
Having a look at the company’s valuation, the company is expected to record -0.50 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CLRB sounds very interesting.
Is the stock of CLRB attractive?
In related news, President and CEO, CARUSO JAMES V bought 5,100 shares of the company’s stock in a transaction that recorded on Mar 04. The purchase was performed at an average price of 1.70, for a total value of 8,659. As the purchase deal closes, the Chief Business Officer, Longcor Jarrod now bought 29,630 shares of the company’s stock, valued at 40,000. Also, President and CEO, CARUSO JAMES V bought 37,037 shares of the company’s stock in a deal that was recorded on Dec 28. The shares were cost at an average price of 1.35 per share, with a total market value of 50,000. Following this completion of disposal, the Chief Financial Officer, Elefant Dov now holds 7,407 shares of the company’s stock, valued at 9,999. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.